(S (NP-SBJ-65 (NP (NN Ras) (NN oncogene) (NN transformation)) (PP (IN of) (NP (JJ human) (NN B) (NNS lymphoblasts)))) (VP (VBZ is) (VP (VBN associated) (NP (-NONE- *-65)) (PP-COOD (PP (IN with) (NP (NN lymphocyte) (NN activation))) (CC and) (PP (IN with) (NP (NP (DT a) (NN block)) (PP (IN of) (NP (NN differentiation)))))))) (. .))
(S (NP-SBJ (DT The) (NN p21ras) (JJ small) (NN GTP) (NN binding) (NNS proteins)) (VP-COOD (VP (VBP participate) (PP (IN in) (NP (NP (JJ signal) (NN transduction)) (PP (IN from) (NP (NN cell) (NN surface) (NNS receptors)))))) (CC and) (VP (VB affect) (NP (NP (JJ neoplastic) (NP-COOD (NP (NN transformation)) (CC and) (NP (NN development)))) (PP (IN in) (NP (JJ many) (JJ different) (NN cell) (NNS types)))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN ras) (NP-COOD (NP (NN transformation)) (CC and) (NP (NN differentiation)))) (PP (IN of) (NP (JJ human) (NN B) (NNS lymphocytes))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-66 (NP (DT the) (JJ constitutive) (NN expression)) (PP (IN of) (NP (DT the) (NN T24) (NN Ha-ras) (NN oncogene))) (PP (IN in) (NP (JJ EBV-immortalized) (NN B) (NNS lymphoblasts)))) (VP (VBD was) (VP (VBN associated) (NP (-NONE- *-66)) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (DT the) (NN interleukin) (CD 2) (NN receptor) (NN alpha) (NN subunit))))) (, ,) (PP (IN with) (NP-COOD (NP (DT an) (JJ impaired) (NN immunoglobulin) (NN gene) (NN expression)) (, ,) (NP (JJ altered) (NN adhesion) (NNS properties)) (CC and) (NP (NP (VBN increased) (NN survival)) (PP (IN in) (NP (JJ serum-free) (NN medium))))))))))) (. .))
(S (SBAR (IN Since) (S (NP-SBJ (NP (NN induction)) (PP (IN of) (NP (DT the) (NN IL-2) (NN receptor) (NN alpha) (NN subunit)))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN hallmark)) (PP (IN of) (NP (NN lymphocyte) (NN activation))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN p21ras)) (ADVP (RB naturally)) (VP (VBZ triggers) (NP (NN B) (NN cell) (NN activation)))))) (. .))
(S (S (NP-SBJ (DT The) (JJ ras-transformed) (NNS lymphocytes)) (VP (VBD displayed) (NP (DT a) (ADJP (RB fully) (JJ functional)) (NN IL-2r)) (, ,) (SBAR (IN as) (S (NP-SBJ-67 (-NONE- *)) (VP (VBN assessed) (NP (-NONE- *-67)) (PP (IN by) (NP (NP (NN c-fos) (NN induction)) (PP-TMP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NN IL-2)))))))))))) (: ;) (S (ADVP (RB nevertheless)) (, ,) (NP-SBJ (PRP they)) (VP (VBD were) (RB not) (NP-PRD (NP (NN growth)) (VP (VBN stimulated) (NP (-NONE- *)) (PP (IN by) (NP (DT this) (NN lymphokine))))))) (. .))
(S (NP-SBJ (NP (DT The) (VBN decreased) (NN expression)) (PP (IN of) (NP (NN immunoglobulin) (NNS genes)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ-68 (DT the) (NN ras) (NN oncogene)) (VP (VBZ blocks) (NP (NP (JJ terminal) (NN differentiation)) (PP (TO to) (NP (NN plasma) (NNS cells)))) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (NP-SBJ (-NONE- *-68)) (VP (VBG inhibiting) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ lymphocyte-specific) (NN transcription) (NNS factors))))))))))) (. .))
(S (ADVP (RB Somewhat) (RB unexpectedly)) (, ,) (NP-SBJ (DT the) (JJ constitutive) (NN p21ras) (NN activity)) (VP (VBD did) (RB not) (VP (VB cause) (NP (NP (DT an) (VBN increased) (NN DNA) (NN binding)) (PP (IN of) (NP (NN transcription) (NNS factors) (NP-COOD (NP (NP (NN PEA1)) (PRN (-LRB- -LRB-) (NP (NN AP1)) (-RRB- -RRB-))) (, ,) (NP (NN PEA3)) (, ,) (NP (NN Oct-2)) (CC or) (NP (NN NF-kB)))))))) (. .))
